Time has been transformed, and we have changed; it has advanced and set us in motion; it has unveiled its face, inspiring us with bewilderment and exhilaration.
T he intense focus at the nexus between elapsed time and outcomes in patients with ST-elevation myocardial infarction (STEMI) signals its far-reaching implications for public health and the healthcare system. In this perspective, we demonstrate not only the time dependence of the 2 principal forms of reperfusion therapy but also how the efficacy of each depends on the baseline risk of the individual in whom it occurs, as well as where the event unfolds in time, space, and context. These variables play a crucial role in determining the choice of best therapy, thereby confirming the admonition that 1 size does not, and could not, fit all individuals in all circumstances at all times. [2] [3] [4] A central issue that bears on the interpretation of the reperfusion literature is which of the various definitions of time is used. We will use the terminology summarized in Table 1 and explore opportunities to modulate the delay incumbent with STEMI treatment.
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Pathobiology of Myocardial Infarction and Time
An ironic divide exists between the precision of timedependent laboratory observations on the extent of myocardial injury and the frustrating imprecision of this metric when applied to humans. The notion of reversible ischemic cell damage after coronary occlusion was framed more than half a century ago. 5 Subsequent canine experiments demonstrated that ischemic necrosis begins in the subendocardium within 20 minutes of coronary occlusion and subsequently proceeds in a transmural wave front of cell death that maximizes within 3 to 6 hours ( Figure 1 ). 6 Although reperfusion achieved within the first hour salvages nearly two thirds of the myocardium at risk, an abrupt decline then occurs such that little or no salvage is evident after 3 to 6 hours of ischemia. The classic studies by Jennings and Reimer 6 also articulated the role of "no reflow" associated with coronary vascular injury with resultant impaired myocardial tissue perfusion; this is now better appreciated as an important subtext of human myocardial infarction with negative consequences.
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Hence, the success or failure of reperfusion is inadequately defined by epicardial patency of the culprit coronary vessel alone.
Although the window for myocardial salvage in the experimental laboratory is virtually closed after 6 hours of coronary occlusion, translating these findings directly to the clinic has proved challenging. A variety of confounding pathophysiological processes are present in acute STEMI that likely account for the apparently wider window of opportunity for reperfusion to exert benefit on the one hand and the diverse clinical responses evident within specific time windows on the other (Table 2) . Moreover, even when salvage of viable myocardium is unlikely, the value of later opening of the infarct-related culprit coronary artery constitutes a probable source of benefit through a variety of other mechanisms. 7, 8 
Reperfusion Therapy: Fibrinolysis
The advent of fibrinolysis revolutionized the care of STEMI by reducing mortality and the attendant morbid complications associated with myocardial infarction. 9 Laboratory data suggested that as time elapsed, the thrombotic coronary occlusion became replete with cross-linked fibrin, thereby increasing its resistance to fibrinolysis. 10 The change in lexicon from "thrombolysis" to "fibrinolysis" was meant to highlight both the differing components of the thrombotic occlusion and the nature of the pharmacological agent(s). 11 As newer drugs with greater fibrin specificity emerged, they proved to be not only more effective in dissolving thrombus but also less sensitive to the passage of time in vitro and in vivo. 10, 12 Early investigations highlighted the differential efficacy of tissue plasminogen activator versus streptokinase on coronary reperfusion; in particular, these studies noted a major attenuation of the effect of streptokinase beyond 3 hours of symptom onset, as well as a lesser reperfusion rate at 90 minutes. Also, a "catch-up" occurred at 180 minutes such that the 2 agents achieved similar patency at this point. 12, 13 Subsequently, Zeymer and colleagues 14 demonstrated divergence among differing fibrinolytic regimens over a 6-hour time frame from symptom onset that showed recombinant tissue plasminogen activator and reteplase to have the best preservation of TIMI (Thrombolysis In Myocardial Infarction) 3 patency 90 minutes after administration. Tenecteplase, given as a single bolus, demonstrates similar efficacy to recombinant tissue plasminogen activator but results in fewer noncerebral bleeding complications and a lesser need for transfusion than tissue plasminogen activator. 15 The ability to 
Table 2. Pathophysiological Factors Modulating Relationship Between Time and Clinical Outcomes
administer tenecteplase as a single 5-second bolus has remarkably advanced the opportunity for prehospital fibrinolytic therapy.
Systematic overview of randomized, placebo-controlled trials of fibrinolysis revealed that maximum benefit was achieved when treatment was given within 60 minutes of symptom onset, which led to the concept of the "golden hour"; thereafter, benefit declined exponentially and largely flattened after 6 hours, which parallels the salvage index defined by Jennings and Reimer ( Figure 1 ). 6, 16 Given that avoidance of myocardial necrosis is the primary goal of reperfusion, the concept of abortion of myocardial infarction is an intriguing phenomenon. In the ASsessment of the Safety and Efficacy of a New Thrombolytic agent (ASSENT-3) trial, we observed 727 (13.3%) of 5470 patients had an aborted myocardial infarction, ie, achieved complete resolution (Ն70%) of their initial ST elevation with minimal or no myocardial enzyme elevation indicative of necrosis. 17 Especially noteworthy was that this was most likely to occur in patients treated within the first hour after symptom onset, during which fully 1 in 4 patients exhibited this entity ( Figure  1 ). Thereafter, a dramatic decline occurred in the frequency of aborted myocardial infarction that showed a pattern remarkably similar to the time dependence of lives saved per thousand patients treated derived from the Fibrinolytic Therapy Trialists (FTT) overview. 9 Further clinical evidence attesting to the benefits of early reperfusion is derived from randomized clinical trials comparing prehospital fibrinolysis (PHF) with in-hospital treatment in a meta-analysis of 6434 patients. 18 The resulting 58-minute reduction in time to treatment, which corresponded to median times to therapy of 104 versus 162 minutes, respectively, highlighted the ability of prehospital therapy to achieve treatment within 2 hours in the majority of individuals. This time saving was associated with a 17% relative, 2.0% absolute mortality reduction at 30 days (pooled odds ratio [OR] 0.83, 95% confidence interval [CI] 0.70 to 0.98, Pϭ0.03), which translated into 1 life saved for every 62 STEMI patients treated with fibrinolytics in the prehospital rather than in-hospital setting. Interestingly, this survival benefit derived from PHF versus in-hospital fibrinolysis mirrors the short-term mortality benefit reported in a systematic overview of 5902 patients that compared the effects of primary percutaneous coronary intervention (PCI) and in-hospital fibrin-specific fibrinolysis. 19 The Register of Information and Knowledge about Swedish Heart Intensive care Admissions (RIKS-HIA) recently reported that PHF was achieved in a median time from symptom onset of 113 minutes versus 165 minutes in the hospital; this translated into a lower 1-year mortality rate with PHF versus in-hospital fibrinolysis ( 7.2% versus 11.8%, multivariable-and propensity-adjusted OR 0.71, 95% CI 0.55 to 0.92, Pϭ0.008). 20
Reperfusion Therapy: Primary PCI
Although experimental evidence and pharmacological reperfusion data conclusively demonstrate that time to treatment is a crucial modulator of patient outcomes, the importance of this relationship when mechanical reperfusion is used has been debated. Clarity on this issue has been hampered by the limited number of patients enrolled in randomized clinical trials with mechanical reperfusion, delay(s) inherent in achieving reperfusion with PCI, and the use of differing metrics for time to treatment (eg, door-to-balloon time), without consideration of time from symptom onset. Specifically, only a small number of primary PCI patients have been studied within the first 2 hours of symptom onset, during which the temporal window for myocardial salvage is maximal. 6 Further insight into the impact on mortality of delay to first balloon inflation has been demonstrated in the 2 largest trials of primary PCI, with additional support from large international registries. Within the DANish multicenter randomized study on fibrinolytic therapy versus Acute Myocardial Infarction (DANAMI-2) study, a 3-fold increase was found in 30-day death, repeat myocardial infarction, or stroke (4.7% versus 12.2%) with delay to randomization. 21, 22 In the Global Utilization of Strategies To open Occluded coronary arteries (GUSTO)-IIB study, in-hospital delay from randomization to first balloon inflation was associated with a 6-fold increase in 30-day mortality when patients treated within 60 minutes of randomization were compared with those treated 90 minutes after randomization (1% versus 6.4%, Pϭ0.035), and delay to PCI was a significant predictor of 30-day mortality (adjusted OR 1.6, 95% CI 1.13 to 2.26 for each time interval, Pϭ0.008). 23 When extended beyond clinical trials to a cohort analysis of 29 222 STEMI patients from 395 National Registry of Myocardial Infarction (NRMI 3/4, 1999 to 2002) hospitals treated with primary PCI within 6 hours of presentation, longer door-to-balloon time was associated with increased in-hospital mortality rates of 3.0%, 4.2%, 5.7%, and 7.4% for door-to-balloon times of Յ90 minutes, 91 to 120 minutes, 121 to 150 minutes, and Ͼ150 minutes, respectively (PϽ0.01 for trend). 24 Further evidence of the impact of delayed time to primary PCI is evident from a separate NRMI analysis restricted to patients transferred for primary PCI from non-PCI centers (who will constitute the majority of patients as PCI becomes increasingly promoted). Within this analysis, those who experienced delay, ie, who underwent PCI Ͼ2 hours after arrival at the initial hospital versus those treated within 2 hours, had an excessive in-hospital risk of recurrent ischemia (10.1% versus 5.8%, PϽ0.0001), cardiogenic shock (8.9% versus 5.1%, PϽ0.001), and mortality (6.2% versus 2.7%, PϽ0.001). 25 When delay to PCI from symptom onset was evaluated over a longer time, ie, 1 year in 1791 STEMI patients from Zwolle, Netherlands, mortality increased 7.5% (adjusted hazard ratio 1.075, 95% CI 1.008 to 1.15, Pϭ0.041) for every 30-minute increase in time from symptom onset to PCI. 26 Suggestions to expand delivery of mechanical reperfusion to the majority of STEMI patients encompass 24-hour/7days-a-week service and increases in the number of interventional centers. 27 However, patients treated during non-working hours (6 PM to 8 AM) encounter greater delay to therapy, have twice the failure rate of primary PCI (TIMI flow grade Ͻ3, 6.9% versus 3.8%, PϽ0.01), and have more than a 2-fold increased 30-day mortality rate (4.2% versus 1.9%, PϽ0.01). 28 Furthermore, an established inverse relationship exists between outcomes of STEMI patients treated with primary PCI in low-volume centers or by interventionalists. 29, 30 Hence, expansion of such facilities requires a delicate balance between the need to maintain adequate PCI center and operator volume to ensure high quality and the impetus/rationale for widespread proliferation of primary PCI centers. Although the current flurry of activity toward better communication and transport of STEMI patients between community and tertiary centers, with a view to shortening door-to-balloon times, is laudable, it remains only 1 piece of a larger whole required to optimize care. 31 Hence, it is desirable to move the healthcare system more proximally into the field, as we and others in North America have done, where expansion and enhancement of prehospital diagnosis, triage, treatment, and initiation of definitive reperfusion strategies in the prehospital environment provide key opportunities to improve STEMI patient outcomes. [32] [33] [34] [35] [36] This model follows the well-established and highly effective prehospital system pioneered in France and used elsewhere. 37 The results of the ASSENT-4 PCI trial, a simultaneously published quantitative overview, 38 and the subsequent randomized Facilitated INtervention with Enhanced reperfusion Speed to Stop Events (FINESSE) trial do not support routine facilitation with either full-dose fibrinolysis or abciximab, with or without half-dose fibrinolytic therapy, as pharmacological strategies to address delay to PCI. 39, 40 The role of routine mechanical cointervention after reperfusion therapy remains unsettled, however, given the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS in AMI) results and the preliminary report from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). 41, 42 Interestingly, when we tested the hypothesis that a baseline Q wave was a physiologically based proxy for the evolutionary stage of STEMI, some insight into the unexpected hazard in the fibrinolyticfacilitated arm of ASSENT-4 PCI emerged. 43 Specifically, we found that those facilitated tenecteplase patients who presented Ͼ3 hours after symptom onset with Q waves not only had less ECG and angiographic evidence of reperfusion before PCI but had worse 90-day outcomes than others in the same treatment group. We presume such patients had more mature organized coronary thrombus that was less amenable to resolution with fibrinolysis and were mainly exposed to the prothrombotic effects and bleeding hazard of fibrinolysis. Although routine mechanical cointervention immediately after fibrinolysis in low-risk or successfully reperfused patients seems unwise, this is clearly not the case in those who meet the recently described criteria for rescue in the 2007 focused update of the American College of Cardiology/American Heart Association 2004 STEMI guidelines or those at continuing high risk. 44, 45 
Comparison of Reperfusion Therapies
Over the past 2 decades, the impact of fibrinolysis versus primary PCI and the influence of time to treatment on parameters of efficacy have been assessed frequently. Schomig and coworkers examined pharmacological versus mechanical interventions and their relationship to the interval between time to treatment and myocardial salvage in the Stent versus Thrombolysis for Occluded coronary arteries in Patients with Acute Myocardial Infarction (STOP AMI) trials. 46 They concluded that the extent of salvage is less dependent on the passage of time with primary PCI than with pharmacological therapy. Although a similar salvage index in those treated within the first tertile of time from symptom onset (ie, within 165 minutes) was found, a progressive subsequent decline in salvage unfolded for fibrinolysis but not PCI. The small sample size (nϭ264) and heterogonous approach to pharmacological therapy, as well as the unusual pattern of time to treatment, are reasons for caution in interpreting these results. More specifically, the door-toneedle times achieved were a median of 35 minutes (interquartile range 25 to 45 minutes), ie, beyond current guideline recommendations, whereas the door-to-balloon time was a remarkably short 65 minutes (interquartile range 50 to 85 minutes), thereby ensuring an unusually brief interval between the delivery of the 2 differing strategies. This temporal paradox in which door-to-balloon times were shortest and door-to-needle times longest in hospitals with the greatest primary PCI specialization has been documented previously in NRMI-4. 47 In an attempt to overcome the limitations of prior aggregate-level meta-analyses comparing fibrinolysis and primary PCI, the Primary Coronary Angioplasty versus Thrombolysis (PCAT)-2 trialists used individual patient data to better gauge the influence of time to treatment (Table 3) . 48 Overall, primary PCI was consistently associated with lower 30-day mortality than fibrinolysis, regardless of presentation or treatment delay (7.9% versus 5.3%, adjusted OR 0.63, 95% CI 0.42 to 0.84, PϽ0.001). The PCAT-2 trialists noted several caveats, 1 of which was exclusion of the Comparison of Angioplasty and Prehospital Thrombolysis In acute Myocardial infarction (CAPTIM) study. 49 They also observed that both the DANAMI-2 and Atlantic Cardiovascular Patient Outcomes Research Team (C-PORT) trials were discontinued prematurely owing to better outcomes in patients randomized to PCI; this was largely accounted for by higher reinfarction rates, yet procedure-related reinfarctions were excluded. 21, 50 Additionally, several trials were perceived likely to exclude "off-hours" patient entry, for which longer delays and worse outcomes with PCI would be expected. The relatively small number of patients assessed in the first 2 hours after symptom onset and the heterogeneity of fibrinolytic mortality over the time windows studied also raises questions about the gener-alizability of the PCAT-2 findings, perhaps accounting for their conclusion, ie, "one treatment does not fit all: time matters." 45 As evident in Table 3 , patients studied early, ie, within the first 2 to 3 hours in the CAPTIM and WEST (Which Early ST elevation myocardial infarction Therapy) trials, which were not included in PCAT-2 comparing primary PCI with a strategic pharmacological approach that included protocol-defined mandatory rescue, had similar or lesser mortality than PCI-treated patients and a lower frequency of secondary end points, including shock and heart failure. 51, 52 Registry and cohort studies involving the 2 reperfusion strategies ( Table 3 ) consistently show improved mortality outcomes with shorter symptom duration in both therapeutic strategies. This was particularly evident with PHF delivered to patients admitted within 3.5 hours of the time from symptom onset in the French Nationwide USIC 2000 Registry and a more recent 2005 follow-up report comparing PHF (with liberal mechanical cointervention) to primary PCI within 2 hours of symptom onset. 37, 53 Although observations from the RIKS-HIA between 2001 and 2004 indicated a need to expand PHF treatment given its favorable outcomes with primary PCI, another RIKS-HIA report later the same year spanning 1999 to 2004 reached a different conclusion, ie, it suggested a benefit of PCI over PHF (Table 3 ). 20, 54 The key role that time from symptom onset plays on the one hand and the efficiency with which reperfusion therapy is delivered on the other are central to a better understanding of the results of this registry. Noteworthy in the latter report for patients evaluated within 2 hours from symptom onset, however, is the very short interval, ie, Ϸ22 minutes between delivery of the 2 reperfusion modalities (PHF median 1 hour 13 minutes, primary PCI 1 hour 35 minutes). Within this same time frame, much less than the usual savings in time (Ϸ17 minutes) was available from symptom onset to the start of in-hospital fibrinolysis (1 hour 30 minutes) versus PHF (1 hour 13 minutes) and no difference (3 hours 45 minutes versus 3 hours 40 minutes) was found in those treated 2 hours after symptom onset. The impact of treatment delay on 6-month mortality was examined in a prospective cohort study among 3959 STEMI patients from the Global Registry of Acute Coronary Events (GRACE) who presented within 6 hours of symptom onset and were treated with either a fibrin-specific fibrinolytic or primary PCI. Multivariable analysis revealed a higher mortality for both cohorts with delay in treatment; importantly, however, the impact of each 10-minute delay in door-toneedle time (between 30 and 60 minutes) for fibrinolysis was 0.30% (95% CI 0.22% to 0.40%), whereas for PCI, a 10-minute delay in door-to-balloon time (between 90 and 150 minutes) had an impact of 0.18% (95% CI 0.08% to 0.35%), which emphasizes the differential effect of treatment delays between these 2 therapies on outcome. 55 Time sensitivity to both forms of reperfusion has been reemphasized in a contemporary 3-state regional approach to STEMI care centered from the Mayo Clinic. 56 In that report, door-to-balloon times Ͼ2 hours were associated with a nearly 3-fold increase in in-hospital mortality with PCI (12.5% versus 4.8%), whereas with fibrinolysis, door-to-needle times exceeding 1 hour resulted in a dramatic rise in hospital mortality to 9.1% (compared with 1.1% with door-to-needle times Ͻ30 minutes).
Time-Risk Relationships
Whereas considerable attention has been directed toward issues associated with delay to PCI, less attention has been given to patient risks incumbent on the requisite interhospital transport for PCI; indeed, some trials included in the systematic overview were selective with regard to patient suitability for interhospital transport and what time of day randomization occurred. 21, 50, 57 Because the DANAMI-2 study was the largest contributor to the systematic overview to support primary PCI as preferred therapy, it deserves reevaluation. 21 In a previous critique of DANAMI-2, we noted that patient inclusion criteria, management of the fibrinolytic arm, and end-point definitions may have affected the outcome; moreover, 37% of patients screened were at "high-risk for potential ambulance transport" and thus were excluded. 58 One feature of the PCI versus fibrinolysis overview rarely noted in current perspectives is the 2% absolute excess (7% versus 5%, Pϭ0.032; OR 1.30, 95% CI 1.02 to 1.65) in major bleeds with PCI, many of which required transfusion. Given current appreciation of the late hazard of excess bleeding and transfusion (unaccounted for in short-term 30-day follow-up), it seems prudent that when making therapeutic choices, one consider not only the risks of fibrinolysis but also the risks of primary PCI related to bleeding, vascular access, and cardiac, cerebral, and renal complications. 19, 59 It is now clear that the original view that reperfusion with PCI and STEMI was resistant to elapsed time was confounded by patients with low baseline risk, as demonstrated in a single Italian institution and subsequently from the NRMI registry. 24, 60 In Ͼ15 000 patients from the Intravenous nPA (lanoteplase) for Treatment of Infarcting Myocardium Early (InTIME)-2 study, Morrow et al 61 developed a risk score for 30-day mortality and demonstrated that the large majority of mortality was accounted for by the 1 in 5 patients who had a TIMI risk score Ն5. Hence, baseline risk strongly intersects with time to reperfusion in the STEMI nexus, thereby affecting choice of therapy ( Figure 2) . Given that increased baseline risk favors the use of mechanical intervention, the 3-year follow-up of DANAMI-2 provides additional insight over the original 30-day outcomes, strongly underscoring how baseline risk modulates clinical outcomes (TIMI risk score-treatment interaction Pϭ0.008). 62 As seen in Figure 3 , the 1 in 4 patients at high risk (ie, TIMI Ն5) derived a clear 3-year mortality benefit from PCI versus fibrinolysis (25.3% versus 36.2%, Pϭ0.02; hazard ratio 0.66, 95% CI 0.45 to 0.94), whereas the large majority of patients did not; in fact, the trend for these other patients was for a better outcome with fibrinolysis (ie, 3-year mortality was 8.0% with PCI and 5.6% with fibrinolysis, Pϭ0.11; hazard ratio 1.44, 95% CI 0.91 to 2.27). As was the case with the excess hazard associated with bleeding, this provides another key example about the relationship of time and reperfusion choices, ie, when is the best time to assess outcomes? When the TIMI risk score was applied to the NRMI 3 database, 73% of all reperfused STEMI patients were found to be at low risk, ie, TIMI risk score Ͻ5. 63 Hence, the majority of STEMI patients are not at high risk (even within trials that attempt to enroll them [eg, DANAMI-2]). We contend that this STEMI risk has major implications for the choice of reperfusion therapies. Pinto et al 64 assessed the impact of PCI-related reperfusion delay across cohorts of patients in NRMI 2 to 4 with various risk factors (anterior versus nonanterior infarction and age Ͼ65 or Ͻ65 years) and further classified them into those presenting before versus Ͼ2 hours after symptom onset. This analysis demonstrated that in young patients with low risk of bleeding, the point at which PCI-related reperfusion delay and fibrinolysis became equivalent was even less than the 60 minutes proposed by others. In older patients, this balance appeared swayed toward a longer acceptable delay until the point at which the 2 therapies became equivalent. Although from a nonrandomized registry, this report further supports the risk in modulating the "acceptable" PCI-related reperfusion delay.
There remains little doubt that patients at high risk, such as those with congestive heart failure and shock, and those with contraindications to fibrinolysis are best served by early PCI. However, inordinate delay between the time from symptom onset and effective reperfusion with PCI may prove deleterious, especially among the majority of STEMI patients at relatively low risk.
Reperfusion Therapy: Future Prospects
The logistics associated with the conduction of comparative randomized reperfusion trials and the challenges in applying their findings to the broader population of STEMI patients are considerable (Table 4 ). A variety of ancillary data from international registries are useful in providing some context about the generalizability of the data from clinical trials. Although application of fibrinolysis in the elderly has raised concern in some quarters, the FTT overview confirms that despite a lesser relative reduction in mortality, the greatest absolute benefit from this therapy in the window up to 12 hours from symptom onset occurs in patients Ն75 years of age, among whom 34 lives per 1000 patients treated are saved versus 28 for those Ͻ75 years of age. 3, 9, 65 Data from nearly 7000 patients Ͼ75 years old in the Swedish registry also support this by indicating that compared with no reperfusion therapy, fibrinolysis saves 40 lives per 1000 patients treated. 66 In the only randomized trial of primary PCI versus in-hospital fibrinolysis for patients Ն70 years of age, no difference between treatments was evident in the primary composite end point of death or disabling stroke. 67 Remarkably, these observations reinforce the benefit accrued by reperfusion in older patients despite the increased risks associated with either reperfusion modality. 66, 68 Perhaps it is the elderly who provide the best example of Hobson's choice or the risk-treatment paradox and constitute a major element of the undertreated and understudied STEMI population. 69 As developed in Figure 2 , a variety of situational and personal factors appear especially influential in modulating the delay between symptom onset and the summoning of medical assistance. 70, 71 Despite concerted efforts through public education programs, including a clinical trial that aimed to abbreviate the time from symptom onset to medical treatment, delay from symptom onset to presentation remains the single most important component of timely therapy. 72 Perception of elapsed time in a given STEMI patient remains a genuine conundrum. The presence of a baseline Q wave on the presenting ECG is known to be independent of time from symptom onset to therapy as a predictor of early epicardial culprit vessel TIMI flow and 30-day mortality. 73, 74 We believe that undertreatment of STEMI patients, especially when time from symptom onset is perceived as late or unavailable, could be addressed in part by the use of the baseline Q wave as another indicator of the stage of evolution of infarction.
Recognition that both reperfusion strategies have central roles to play and can be complementary is the key to optimizing care for all STEMI patients. As succinctly articulated in the 2004 American College of Cardiology/American Heart Association STEMI guidelines, "Given the current literature, it is not possible to say definitively that a particular reperfusion approach is superior for all patients, in all clinical settings, at all times of day. The main point is that some type of reperfusion therapy should be selected for all appropriate patients with suspected STEMI. The appropriate and timely use of some reperfusion therapy is likely more important than the choice of therapy." 4 If STEMI prognosis is to be improved at a public health level and the goal of reperfusion within 2 hours of symptom onset achieved, it is clear that a major shift in health systems toward earlier prehospital diagnosis, treatment, and triage must occur. 4, 75, 76 Time stands as a key modulator of the decision on which reperfusion therapy to choose. It cannot stand alone, however, and must be framed in the context of the baseline risks and circumstances depicted in Figure 2 . As Gibran eloquently opined about time, the dramatic advances in STEMI care have truly been transforming, stimulating changes in international healthcare systems and inspiring a new spirit of collaboration among healthcare providers. These developments have not only enhanced the care of thousands of STEMI patients worldwide but have set in motion creative efforts and opportunities to improve outcomes across a broad range of life-threatening, time-sensitive cardiovascular conditions.
